NEW YORK (GenomeWeb News) – Nextcode Health officially launched today, saying it has licensed technology developed by Decode Genetics that it will use to accelerate the diagnosis of cancer through sequencing-based data.

The Cambridge, Mass.-based company also said that it has secured $15 million in Series A financing. Investors in the round included Polaris Partners and Arch Venture Partners, and the financing will be used to scale up the integration of its genomics services into clinical settings.

A Nextcode spokesperson confirmed the company is a spinout of Decode.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.